Published in J Clin Sleep Med on December 15, 2011
In the Zzz zone: the effects of Z-drugs on human performance and driving. J Med Toxicol (2013) 0.99
Parkinson's disease and sleep/wake disturbances. Parkinsons Dis (2012) 0.78
Managing insomnia: an overview of insomnia and pharmacologic treatment strategies in use and on the horizon. Drugs Context (2013) 0.77
Sleep self-intoxication and sleep driving as rare zolpidem-induced complex behaviour. Int J Legal Med (2014) 0.76
While You Were Sleepwalking: Science and Neurobiology of Sleep Disorders & the Enigma of Legal Responsibility of Violence During Parasomnia. Neuroethics (2015) 0.76
Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit. F1000Res (2016) 0.76
Is suvorexant a better choice than alternative hypnotics? F1000Res (2015) 0.75
Is Zolpidem Associated with Increased Risk of Fractures in the Elderly with Sleep Disorders? A Nationwide Case Cross-Over Study in Taiwan. PLoS One (2015) 0.75
Residual Effects of Sleep Medications Are Commonly Reported and Associated with Impaired Patient-Reported Outcomes among Insomnia Patients in the United States. Sleep Disord (2015) 0.75
In-flight emergency. Ann Emerg Med (2015) 0.75
Practice parameters for the psychological and behavioral treatment of insomnia: an update. An american academy of sleep medicine report. Sleep (2006) 3.12
Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch Intern Med (2004) 2.16
Precipitating factors of somnambulism: impact of sleep deprivation and forced arousals. Neurology (2008) 1.99
Alcohol-induced sleepwalking or confusional arousal as a defense to criminal behavior: a review of scientific evidence, methods and forensic considerations. J Sleep Res (2007) 1.87
Sleepwalking associated with zolpidem. J Clin Psychopharmacol (1994) 1.87
Night terrors, sleepwalking, and confusional arousals in the general population: their frequency and relationship to other sleep and mental disorders. J Clin Psychiatry (1999) 1.73
Effects of after-midnight intake of zolpidem and temazepam on driving ability in women with non-organic insomnia. Sleep Med (2003) 1.55
Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol (2000) 1.47
Sleep driving: sleepwalking variant or misuse of z-drugs? Sleep Med Rev (2011) 1.45
Hypnosedative-induced complex behaviours : incidence, mechanisms and management. CNS Drugs (2008) 1.42
Prevalence and genetics of sleepwalking: a population-based twin study. Neurology (1997) 1.34
Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs (1990) 1.29
Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem. J Clin Sleep Med (2009) 1.28
Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol (2002) 1.25
A parasomnia overlap disorder involving sleepwalking, sleep terrors, and REM sleep behavior disorder in 33 polysomnographically confirmed cases. Sleep (1997) 1.21
Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem. J Sleep Res (2009) 1.13
Zolpidem-polysomnographic study of the effect of a new hypnotic drug in sleep apnea syndrome. Pharmacol Biochem Behav (1988) 1.10
Evidence of dissociated arousal states during NREM parasomnia from an intracerebral neurophysiological study. Sleep (2009) 1.09
A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. Br J Clin Pharmacol (1999) 1.09
Comparative tolerability of newer agents for insomnia. Drug Saf (2009) 1.06
New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (omega) receptor subtypes. Psychopharmacology (Berl) (1999) 0.97
Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. J Clin Psychopharmacol (2000) 0.94
Impairment related to blood drug concentrations of zopiclone and zolpidem compared to alcohol in apprehended drivers. Accid Anal Prev (2009) 0.93
Zolpidem and traffic safety - the importance of treatment compliance. Curr Drug Saf (2007) 0.92
Residual effect of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades. Psychopharmacology (Berl) (1999) 0.92
Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring. Psychopharmacology (Berl) (2005) 0.91
Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers. J Clin Psychopharmacol (1996) 0.89
Prevalence and cost of insomnia in a state Medicaid fee-for-service population based on diagnostic codes and prescription utilization. Sleep Med (2010) 0.87
Concentrations of scheduled prescription drugs in blood of impaired drivers: considerations for interpreting the results. Ther Drug Monit (2007) 0.85
Zolpidem and driving impairment. J Forensic Sci (2001) 0.83
Effects of zolpidem, a new imidazopyridine hypnotic, on the acquisition of conditioned fear in mice. Comparison with triazolam and CL 218,872. Psychopharmacology (Berl) (1986) 0.81
Zolpidem-induced sleep-driving. Am J Med (2008) 0.80
Current status of hypnotic prescribing habits in the United States. Psychiatry (Edgmont) (2007) 0.78
NREM parasomnias. Handb Clin Neurol (2011) 0.77